[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629215":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":30,"locations":36,"responsibleParty":61,"collaborators":10,"id":65,"slug":10,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":10,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"TROP2 ADC",null,[12,13,14],"Drug: Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan","Diagnostic Test: 68Ga-TROP2 PET\u002FCT Imaging","Diagnostic Test: 18F-FDG PET Imaging",[16,21,26],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DRUG","Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan","TROP2-targeted antibody-drug conjugate administered according to standard clinical dosing schedule until disease progression or unacceptable toxicity.",[9],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","68Ga-TROP2 PET\u002FCT Imaging","Whole-body PET imaging using 68Ga-labeled TROP2-targeting tracer to assess in vivo TROP2 expression prior to TROP2 ADC treatment initiation.",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"18F-FDG PET Imaging","Standard 18F-FDG PET imaging performed prior to TROP2 ADC treatment to assess tumor metabolic activity.",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Biyun Wang","CONTACT","021-64175590","wangbiyun0107@hotmail.com",[37,53],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","200032","China",{"type":45,"coordinates":46},"Point",[47,48],121.45806,31.22222,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":34,"phoneExt":10,"email":35},"Biyun wang",{"facility":38,"status":54,"city":40,"state":10,"zip":42,"country":43,"cosmosGeoPoint":55,"geoPoint":57,"contacts":58},"NOT_YET_RECRUITING",{"type":45,"coordinates":56},[47,48],{"lat":48,"lon":47},[59],{"name":32,"role":33,"phone":60,"phoneExt":10,"email":35},"18017312387",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Biyun Wang, MD","Professor","100629215",false,"NCT07471776","Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","Inclusion Criteria:\n\n* Patients diagnosed with advanced\u002Fmetastatic HER2-negative breast cancer with confirmed metastatic disease, regardless of being de novo diagnosed or progressed from a non-metastatic stage.\n* Patients who are planned to receive anti-TROP2 antibody-drug conjugate (ADC) therapy (e.g., sacituzumab govitecan or datopotamab deruxtecan) as part of routine clinical care.\n* Patients who will undergo protocol-defined \\^68Ga-TROP2 PET\u002FCT and \\^18F-FDG PET\u002FCT during the study (baseline imaging, with repeat imaging per protocol if applicable).\n* Adult patients (≥18 years) who are able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Patients with incomplete medical records or inability to complete the required imaging assessments.\n* Patients with prior exposure to an anti-TROP2 ADC.\n* Patients with known contraindications to PET\u002FCT or known allergy to \\^18F-FDG or the \\^68Ga-TROP2 tracer (or their components).\n* Patients who are pregnant or breastfeeding.\n* Patients diagnosed with secondary primary tumors (other active malignancies), as determined by the investigator.","ALL","18 Years",{"count":73,"type":74},45,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","This study aims to evaluate whether \\^68Ga-TROP2 PET\u002FCT, combined with \\^18F-FDG PET\u002FCT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer. Baseline and dynamic imaging parameters will be used to develop prediction models (primary endpoint: AUC), and their associations with clinical outcomes and tumor TROP2 status will be explored.",[80],"Metastatic Breast Cancer ( HER2 Negative)","2026-03-10",{"date":83,"type":84},"2026-03-13","ACTUAL",{"date":86,"type":84},"2026-03-11",{"date":88,"type":74},"2029-03-11",{"name":5,"class":6},2]